Changing paradigms in the treatment of chronic lymphocytic leukemia. - Wikidata - awgldk - TriplyDB

Changing paradigms in the treatment of chronic lymphocytic leukemia.

Changing paradigms in the treatment of chronic lymphocytic leukemia.

http://www.wikidata.org/entity/Q37662198

about

The impact of low-dose carcinogens and environmental disruptors on tissue invasion and metastasis Evaluation of bendamustine in combination with fludarabine in primary chronic lymphocytic leukemia cells.Monoclonal antibodies for non-Hodgkin's lymphoma: state of the art and perspectives.Superior efficacy of rituximab-based chemoimmunotherapy as an initial therapy in newly diagnosed patients with B cell indolent lymphomas: long-term results from a single center in China.Demographics, treatment patterns, safety, and real-world effectiveness in patients aged 70 years and over with chronic lymphocytic leukemia receiving bendamustine with or without rituximab: a retrospective study.Optimal pharmacotherapeutic management of chronic lymphocytic leukaemia: considerations in the elderly.Immunotherapy for chronic lymphocytic leukemia in the era of BTK inhibitors.Reduction of complement factor H binding to CLL cells improves the induction of rituximab-mediated complement-dependent cytotoxicity.Renal human organic anion transporter 3 increases the susceptibility of lymphoma cells to bendamustine uptake.

P2860

Q28388257-5D46A22F-381E-4C0F-B1B4-5D80A707932D Q33749652-F3D728E7-AD70-4850-80A8-CE61501DA46E Q34700655-2F372E8A-7265-40A4-87DC-40582A10732B Q35720912-2D8E0777-0A52-495E-A95F-8E6598042065 Q36883352-2657F17A-AE09-417D-9E40-683640DD8822 Q37844139-BB94FAD1-13AA-4F41-9AC1-3319D0374C73 Q38155343-14B3041C-26BE-455F-9805-CB03AD43723B Q41966008-0544632E-D104-4650-BF99-9D46227BF7BD Q53670141-905D3818-3393-4E2F-A1B3-9A65A5AC3264

P2860

Changing paradigms in the treatment of chronic lymphocytic leukemia.

http://www.wikidata.org/entity/Q37662198

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 24 December 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Changing paradigms in the treatment of chronic lymphocytic leukemia.

@en

Changing paradigms in the treatment of chronic lymphocytic leukemia.

@nl

type

label

Changing paradigms in the treatment of chronic lymphocytic leukemia.

@en

Changing paradigms in the treatment of chronic lymphocytic leukemia.

@nl

prefLabel

Changing paradigms in the treatment of chronic lymphocytic leukemia.

@en

Changing paradigms in the treatment of chronic lymphocytic leukemia.

@nl

P1433

Q37662198-777C83B1-0647-4AC5-A0F7-A355ABB1AF62

P1476

Q37662198-7C71E437-2329-4346-91D3-B42E4A7620B7

P2093

Q37662198-3F3B8BAF-933A-4793-895B-517E59BF89F6

Q37662198-D7769463-6DDE-4D74-978C-8E139642B50B

P2860

Q37662198-06C79B2E-B579-465E-9344-8F337E7AA382

Q37662198-0AC16144-2A51-46E9-B072-C5599AC4E3D2

Q37662198-11B527BF-9A6D-4D6E-862A-C95DD30F0D19

Q37662198-144B3C44-0C07-4275-803E-8ADC53F14308

Q37662198-1581E779-6A82-4F76-939A-CB6EFF1A9528

Q37662198-19F21273-586A-400B-B4C4-0A2AB0AF839A

Q37662198-1EAA5D9E-8CFE-4B0D-B768-0A7A67E8BB66

Q37662198-26243996-A092-4CAF-8748-7A53E0C9E239

Q37662198-2A52AA46-6BC8-40B3-9716-261C4A3794A3

Q37662198-341550A6-1DC7-4FF7-84F7-4DBD3BAA33A1

P2888

Q37662198-D1EA212D-E949-4090-9C1D-82B7B2FB330C

P304

Q37662198-ADB53027-FA20-42AD-9188-E6F240F78809

P31

Q37662198-CB4F0989-440C-4A6B-9EC2-2E26612C36D2

P356

Q37662198-33E82F85-1B17-4FA4-ABEE-C0A0764EDC3F

P433

Q37662198-9E48CEAE-EA0D-4366-82E4-A02D9FA8ED92

P478

Q37662198-CB888AA7-5E2E-4E6C-A0A6-F315A3502B7F

P577

Q37662198-DCED274A-B3E6-4C8A-B9D9-42C394680DFC

P5875

Q37662198-2ADEC0A3-EC02-4324-AA49-DEB5B3B7B275

P6179

Q37662198-B4DB0043-76A4-4ED0-9484-2490EF767DDC

P698

Q37662198-5F155A58-BC2B-4AF2-BC2D-1D3795CA05E9

P921

Q37662198-85AA2A46-A540-4545-BDEC-568A1DA2528C

Q37662198-D55B6C74-6E3A-47CC-B8C0-FC273E57EA73

P356

P1433

P1476

Changing paradigms in the treatment of chronic lymphocytic leukemia.

@en

P2093

K A Foon

http://www.w3.org/2001/XMLSchema#string

M J Hallek

http://www.w3.org/2001/XMLSchema#string

P2860

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura

Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia

Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions.

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia.

Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial.

Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients.

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.

Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia.

P2888

P304

500-511

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/LEU.2009.266

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P577

2009-12-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

40768524

http://www.w3.org/2001/XMLSchema#string

P6179

1043472942

http://www.w3.org/2001/XMLSchema#string

P698

20033051

http://www.w3.org/2001/XMLSchema#string

P921